Loading…
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa
Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aerugi...
Saved in:
Published in: | International journal of antimicrobial agents 2009-12, Vol.34 (6), p.589-591 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193 |
---|---|
cites | cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193 |
container_end_page | 591 |
container_issue | 6 |
container_start_page | 589 |
container_title | International journal of antimicrobial agents |
container_volume | 34 |
creator | Shigemi, Akari Matsumoto, Kazuaki Yaji, Keiko Shimodozono, Yoshihiro Takeda, Yasuo Miyanohara, Hiroaki Kawamura, Hideki Orita, Michiyo Tokuda, Koichi Nishi, Junichiro Yamada, Katsushi |
description | Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains. |
doi_str_mv | 10.1016/j.ijantimicag.2009.07.017 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734121107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0924857909003720</els_id><sourcerecordid>734121107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</originalsourceid><addsrcrecordid>eNqNkkuv1CAUgBuj8Y5X_4LBhbpqPdBSysbETHwlN9FEXRMKp1dqCyO06vx76Z2JGhfGFQG-88j5TlE8olBRoO2zsXKj9oubndHXFQOQFYgKqLhV7GgnWCkkrW8XO5CsKTsu5EVxL6URgPK64XeLCypF07Ga7oof-xAjTnpxwZMel--InswYwwE9zkR7S2yI7nRbExKLPrnlePOzfEbivHH5zSAJAzE69vqGLSMml5bcJXmfcLVhDl4nojGu186HpO8XdwY9JXxwPi-LT69efty_Ka_evX67f3FVmkaypbQt5xxsh9AaYP3QgxQ1h8EOWth2wAEYr1tGGZfcaonA9TYi2dUWB01lfVk8PeU9xPB1xbSo2SWD06Q9hjUpUTeUUQoik0_-SWaKy65lGZQn0MSQUsRBHaKbdTwqCmqrrkb1hyC1CVIgVBaUYx-ei6z9jPZ35NlIBh6fAZ2Mnoao84DTL46x7FDwLnP7E4d5eN8cRpWM2zxYF9Esygb3X-08_yuLmZzP2PQFj5jGsEaf7SiqElOgPmwbtS0USIBaMKh_AmGHy7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21159862</pqid></control><display><type>article</type><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><source>ScienceDirect Journals</source><creator>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</creator><creatorcontrib>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</creatorcontrib><description>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2009.07.017</identifier><identifier>PMID: 19748231</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobial use density ; beta-Lactam Resistance ; Biological and medical sciences ; Carbapenems ; Carbapenems - pharmacology ; Carbapenems - therapeutic use ; Cross-resistance ; Drug Utilization - statistics & numerical data ; Humans ; Infectious Disease ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - isolation & purification ; Pseudomonas Infections - microbiology ; Statistics as Topic ; Susceptibility ; Thienamycins - therapeutic use</subject><ispartof>International journal of antimicrobial agents, 2009-12, Vol.34 (6), p.589-591</ispartof><rights>Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2009 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</citedby><cites>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22153758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19748231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shigemi, Akari</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Yaji, Keiko</creatorcontrib><creatorcontrib>Shimodozono, Yoshihiro</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><creatorcontrib>Miyanohara, Hiroaki</creatorcontrib><creatorcontrib>Kawamura, Hideki</creatorcontrib><creatorcontrib>Orita, Michiyo</creatorcontrib><creatorcontrib>Tokuda, Koichi</creatorcontrib><creatorcontrib>Nishi, Junichiro</creatorcontrib><creatorcontrib>Yamada, Katsushi</creatorcontrib><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobial use density</subject><subject>beta-Lactam Resistance</subject><subject>Biological and medical sciences</subject><subject>Carbapenems</subject><subject>Carbapenems - pharmacology</subject><subject>Carbapenems - therapeutic use</subject><subject>Cross-resistance</subject><subject>Drug Utilization - statistics & numerical data</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - isolation & purification</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Statistics as Topic</subject><subject>Susceptibility</subject><subject>Thienamycins - therapeutic use</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkkuv1CAUgBuj8Y5X_4LBhbpqPdBSysbETHwlN9FEXRMKp1dqCyO06vx76Z2JGhfGFQG-88j5TlE8olBRoO2zsXKj9oubndHXFQOQFYgKqLhV7GgnWCkkrW8XO5CsKTsu5EVxL6URgPK64XeLCypF07Ga7oof-xAjTnpxwZMel--InswYwwE9zkR7S2yI7nRbExKLPrnlePOzfEbivHH5zSAJAzE69vqGLSMml5bcJXmfcLVhDl4nojGu186HpO8XdwY9JXxwPi-LT69efty_Ka_evX67f3FVmkaypbQt5xxsh9AaYP3QgxQ1h8EOWth2wAEYr1tGGZfcaonA9TYi2dUWB01lfVk8PeU9xPB1xbSo2SWD06Q9hjUpUTeUUQoik0_-SWaKy65lGZQn0MSQUsRBHaKbdTwqCmqrrkb1hyC1CVIgVBaUYx-ei6z9jPZ35NlIBh6fAZ2Mnoao84DTL46x7FDwLnP7E4d5eN8cRpWM2zxYF9Esygb3X-08_yuLmZzP2PQFj5jGsEaf7SiqElOgPmwbtS0USIBaMKh_AmGHy7w</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Shigemi, Akari</creator><creator>Matsumoto, Kazuaki</creator><creator>Yaji, Keiko</creator><creator>Shimodozono, Yoshihiro</creator><creator>Takeda, Yasuo</creator><creator>Miyanohara, Hiroaki</creator><creator>Kawamura, Hideki</creator><creator>Orita, Michiyo</creator><creator>Tokuda, Koichi</creator><creator>Nishi, Junichiro</creator><creator>Yamada, Katsushi</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><author>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobial use density</topic><topic>beta-Lactam Resistance</topic><topic>Biological and medical sciences</topic><topic>Carbapenems</topic><topic>Carbapenems - pharmacology</topic><topic>Carbapenems - therapeutic use</topic><topic>Cross-resistance</topic><topic>Drug Utilization - statistics & numerical data</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - isolation & purification</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Statistics as Topic</topic><topic>Susceptibility</topic><topic>Thienamycins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shigemi, Akari</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Yaji, Keiko</creatorcontrib><creatorcontrib>Shimodozono, Yoshihiro</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><creatorcontrib>Miyanohara, Hiroaki</creatorcontrib><creatorcontrib>Kawamura, Hideki</creatorcontrib><creatorcontrib>Orita, Michiyo</creatorcontrib><creatorcontrib>Tokuda, Koichi</creatorcontrib><creatorcontrib>Nishi, Junichiro</creatorcontrib><creatorcontrib>Yamada, Katsushi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shigemi, Akari</au><au>Matsumoto, Kazuaki</au><au>Yaji, Keiko</au><au>Shimodozono, Yoshihiro</au><au>Takeda, Yasuo</au><au>Miyanohara, Hiroaki</au><au>Kawamura, Hideki</au><au>Orita, Michiyo</au><au>Tokuda, Koichi</au><au>Nishi, Junichiro</au><au>Yamada, Katsushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>34</volume><issue>6</issue><spage>589</spage><epage>591</epage><pages>589-591</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19748231</pmid><doi>10.1016/j.ijantimicag.2009.07.017</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0924-8579 |
ispartof | International journal of antimicrobial agents, 2009-12, Vol.34 (6), p.589-591 |
issn | 0924-8579 1872-7913 |
language | eng |
recordid | cdi_proquest_miscellaneous_734121107 |
source | ScienceDirect Journals |
subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobial use density beta-Lactam Resistance Biological and medical sciences Carbapenems Carbapenems - pharmacology Carbapenems - therapeutic use Cross-resistance Drug Utilization - statistics & numerical data Humans Infectious Disease Medical sciences Microbial Sensitivity Tests Pharmacology. Drug treatments Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - isolation & purification Pseudomonas Infections - microbiology Statistics as Topic Susceptibility Thienamycins - therapeutic use |
title | Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A50%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20meropenem%20and%20doripenem%20use%20density%20and%20the%20incidence%20of%20carbapenem-resistant%20Pseudomonas%20aeruginosa&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Shigemi,%20Akari&rft.date=2009-12-01&rft.volume=34&rft.issue=6&rft.spage=589&rft.epage=591&rft.pages=589-591&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2009.07.017&rft_dat=%3Cproquest_cross%3E734121107%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21159862&rft_id=info:pmid/19748231&rfr_iscdi=true |